NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

SLNO

Soleno Therapeutics Inc

Apr 09 • 04:00PM ET

63.27

Dollar change +4.23
Percentage change 7.16	%

Healthcare • Biotechnology • USA • NASD

Peers: VKTX RZLT MDGL LGND KURA ARDX ASRT ENTA PDSB BTAI

| Held by: VTI IWM XBI VXF IWO DWAS SCHA VTWO VHT LFSC

Index	RUT	P/E	-	EPS (ttm)	-4.26	Insider Own	21.94%	Shs Outstand	45.70M	Perf Week	-14.12%
Market Cap	2.90B	Forward P/E	342.00	EPS next Y	0.18	Insider Trans	-22.86%	Shs Float	35.80M	Perf Month	41.29%
Income	-175.85M	PEG	-	EPS next Q	-0.89	Inst Own	90.92%	Short Float	13.02%	Perf Quarter	36.89%
Sales	0.00M	P/S	-	EPS this Y	39.57%	Inst Trans	7.27%	Short Ratio	4.16	Perf Half Y	32.84%
Book/sh	5.36	P/B	11.80	EPS next Y	106.99%	ROA	-68.74%	Short Interest	4.66M	Perf Year	56.96%
Cash/sh	6.36	P/C	9.96	EPS next 5Y	-	ROE	-87.35%	52W Range	36.61 - 74.00	Perf YTD	40.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.19%	ROI	-59.13%	52W High	-14.50%	Beta	-2.59
Dividend TTM	-	Quick Ratio	15.68	Sales past 5Y	0.00%	Gross Margin	-	52W Low	72.82%	ATR (14)	5.36
Dividend Ex-Date	-	Current Ratio	15.68	EPS Y/Y TTM	-43.20%	Oper. Margin	-	RSI (14)	55.81	Volatility	11.80% 7.58%
Employees	92	Debt/Eq	0.22	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.11	Target Price	99.78
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	-288.57%	Payout	-	Rel Volume	2.85	Prev Close	59.04
Sales Surprise	-	EPS Surprise	-30.42%	Sales Q/Q	-	Earnings	Feb 27 AMC	Avg Volume	1.12M	Price	63.27
SMA20	7.43%	SMA50	21.38%	SMA200	26.84%	Trades		Volume	3,119,071	Change	7.16%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Resumed	Stifel	Buy	$74
Dec-02-24	Reiterated	Stifel	Buy	$74
Dec-02-24	Reiterated	Robert W. Baird	Outperform	$72
Sep-03-24	Initiated	H.C. Wainwright	Buy	$70
May-10-24	Initiated	Robert W. Baird	Outperform	$72
Feb-05-24	Initiated	Piper Sandler	Overweight	$93
Jan-23-24	Initiated	Stifel	Buy	$63
Nov-21-23	Resumed	Guggenheim	Buy	$40
Sep-29-20	Initiated	Guggenheim	Buy	$8
Jan-10-20	Initiated	Craig Hallum	Buy	$8
Dec-23-19	Initiated	Oppenheimer	Outperform	$10
Feb-13-18	Reiterated	Maxim Group	Buy	$8 → $4

Show Previous Ratings

Mar-29-25 10:39PM	Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? (Insider Monkey)
Mar-28-25 10:30PM	Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? (Insider Monkey) +6.83%
04:25AM	Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? (Insider Monkey)
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) +37.61%
04:11PM	Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger (Bloomberg)
03:40PM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
03:40PM	Soleno wins FDA approval for Prader-Willi hyperphagia treatment (Pharmaceutical Technology)
02:50PM	Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SeekingAlpha)
12:11PM	Soleno stock skyrockets on FDA drug approval (Yahoo Finance Video)
08:46AM	SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug (Zacks)
Mar-26-25 05:15PM	Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome (GlobeNewswire)
01:15PM	First Prader-Willi drug to reduce hunger approved by FDA (BioPharma Dive)
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha)
Feb-27-25 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire) +8.51%
Jan-29-25 04:05PM	Soleno Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-13-25 04:26PM	Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential? (Insider Monkey)
04:05PM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Dec-17-24 04:05PM	Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC (GlobeNewswire)
Nov-27-24 08:00AM	Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
07:40AM	FDA delays decision of Solenos Prader-Willi syndrome drug (Pharmaceutical Technology)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-26-24 10:08AM	Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment (GuruFocus.com)
08:30AM	Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (GlobeNewswire)
Nov-14-24 04:05PM	Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 (GlobeNewswire)
Nov-06-24 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-28-24 08:00AM	Soleno Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-25-24 02:44PM	Lamb Weston, Adecoagro, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-21-24 08:00AM	Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. (GlobeNewswire)
Oct-18-24 06:41PM	TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-16-24 08:44AM	Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR (Insider Monkey)
Oct-15-24 06:10PM	Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment (Insider Monkey)
Oct-10-24 07:04PM	Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc. (GuruFocus.com) +7.78%
06:29PM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Oct-08-24 06:29PM	Why Soleno Therapeutics Stock Blasted 9% Higher Today (Motley Fool) +9.11%
08:30AM	Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome (GlobeNewswire)
Oct-03-24 01:03PM	Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc (GuruFocus.com)
Sep-16-24 04:05PM	Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-12-24 01:34AM	Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc. (GuruFocus.com)
Aug-28-24 10:13AM	Soleno wins FDA priority review for Prader-Willi therapy (Pharmaceutical Technology)
Aug-27-24 08:51PM	Soleno Therapeutics, Inc. (SLNO): One of Oppenheimer's Top Stock Picks For the Next 12 Months (Insider Monkey) +6.31%
08:00AM	Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (GlobeNewswire)
Aug-19-24 04:17PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.72%
Aug-15-24 08:00AM	Soleno Therapeutics Announces Updates to its Board of Directors (GlobeNewswire)
Aug-07-24 11:53PM	SLNO Stock Earnings: Soleno Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.93%
04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-17-24 08:56AM	These Stock Winners Are Strong Buys With More Room Left to Run (TipRanks) -5.57%
Jun-28-24 08:00AM	Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome (GlobeNewswire)
Jun-24-24 05:18PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 08:00AM	Soleno Therapeutics Set to Join Russell 3000 Index (GlobeNewswire)
May-22-24 04:05PM	Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 (GlobeNewswire)
08:00AM	Soleno Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-24 08:00AM	Soleno Therapeutics Stands with the Prader-Willi Syndrome Community (GlobeNewswire)
02:22AM	15 Stocks That Will 10x in 5 Years According to the Analysts (Insider Monkey)
May-10-24 07:16AM	Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target (MT Newswires) -5.56%
May-09-24 11:54PM	SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-03-24 05:46AM	Soleno Therapeutics Prices $138 Million Stock Offering (MT Newswires) -8.35%
May-02-24 10:32PM	Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock (GlobeNewswire)
04:01PM	Soleno Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Apr-30-24 08:00AM	Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome (GlobeNewswire)
Apr-29-24 11:12AM	Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment (MT Newswires) +20.16%
11:11AM	Why Soleno Therapeutics Stock Is Skyrocketing Today (Motley Fool)
08:00AM	Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) (GlobeNewswire)
Apr-19-24 04:05PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-04-24 01:54AM	CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO) (GuruFocus.com)
01:54AM	Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO) (GuruFocus.com)
Mar-08-24 04:05PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-24 10:53PM	SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 08:00AM	Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-14-24 08:50AM	Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-05-24 10:10AM	Charter downgraded, Cigna upgraded: Wall Street's top analyst calls (The Fly) +5.91%
Feb-01-24 08:00AM	Soleno Therapeutics to Present at Upcoming February Investor Conferences (GlobeNewswire)
Jan-29-24 04:05PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-26-24 08:50AM	Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going (Zacks)
Jan-24-24 08:00AM	Soleno Therapeutics Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Jan-10-24 08:50AM	Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength (Zacks)
Jan-05-24 08:00AM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-21-23 06:59PM	Why Soleno Therapeutics Stock Ticked Higher on Thursday (Motley Fool)
Dec-15-23 09:30AM	Growth Stocks Under $50 for December 2023 (Investopedia)
Dec-14-23 03:44PM	Take Profit: 3 Stocks to Sell That Are Up More Than 200% in 2023 (InvestorPlace)
03:05PM	Insider Sell Alert: CEO Bhatnagar Anish Unloads 93,408 Shares of Soleno Therapeutics Inc (SLNO) (GuruFocus.com)
07:00AM	3 Stock Winners That Are Up 500% or More in 2023 (InvestorPlace)
Dec-01-23 03:06AM	Insider Sell Alert: CFO James Mackaness Sells 8,081 Shares of Soleno Therapeutics Inc (SLNO) (GuruFocus.com)
Nov-27-23 01:02PM	Feeling Lucky? 5 Jackpot Stocks to Buy for 2024. (InvestorPlace)
Nov-20-23 03:06PM	3 Biotech Stocks With Big-Time Breakthrough Potential (InvestorPlace) +8.50%
Nov-10-23 04:05PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-23 08:00AM	Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:00AM	Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome (GlobeNewswire)
Nov-01-23 11:30AM	Top Stocks for November 2023 (Investopedia)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-16-23 04:07PM	The Ten Most-Shorted Stocks Include Huge Market Movers In 2023 (Investor's Business Daily)
08:01AM	The 10 Most Shorted Stocks Include 3 Tesla Rivals, But Not TSLA (Investor's Business Daily)
Oct-06-23 06:25PM	Xerox, Mastercraft Boat, and More Stocks See Action From Activist Investors (Barrons.com) +10.61%
Oct-04-23 06:16PM	Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium (GlobeNewswire) -6.15%
04:05PM	Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium (GlobeNewswire)
Oct-03-23 08:00AM	Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505% (Investor's Business Daily)
Oct-02-23 04:05PM	Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.27%
Sep-28-23 09:58AM	Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data (Zacks) +33.48%
08:30AM	Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants (GlobeNewswire)
Sep-27-23 06:08PM	Daily Market Wrap Up: Micron Technology's Mixed Guidance, Morgan Stanley's Dividend Picks, and ... (GuruFocus.com) -22.87%
04:55PM	Why Shares of Soleno Therapeutics Dropped on Wednesday (Motley Fool)

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hirano Patricia C	SEE REMARKS	Apr 01 '25	Sale	70.11	3,782	265,156	27,036	Apr 02 05:38 PM
PATRICIA HIRANO	Officer	Apr 01 '25	Proposed Sale	70.11	3,782	265,156		Apr 01 04:16 PM
Pauls Matthew	Director	Mar 28 '25	Option Exercise	4.60	5,937	27,310	12,437	Mar 31 07:24 PM
Pauls Matthew	Director	Mar 28 '25	Sale	71.55	5,937	424,797	6,500	Mar 31 07:24 PM
Yen Kristen	SEE REMARKS	Mar 27 '25	Option Exercise	4.97	40,638	201,966	101,774	Mar 31 07:23 PM
Yen Kristen	SEE REMARKS	Mar 27 '25	Sale	66.77	95,500	6,376,789	28,143	Mar 31 07:23 PM
Manning Meredith	Chief Commercial Officer	Mar 27 '25	Option Exercise	46.31	37,000	1,713,470	82,351	Mar 31 07:21 PM
Manning Meredith	Chief Commercial Officer	Mar 27 '25	Sale	67.28	45,249	3,044,343	45,351	Mar 31 07:21 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Mar 27 '25	Option Exercise	11.72	70,000	820,125	175,176	Mar 31 07:20 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Mar 27 '25	Sale	69.44	90,622	6,293,177	105,176	Mar 31 07:20 PM
Huang Michael F.	Sr. VP of Clinical Development	Mar 27 '25	Option Exercise	21.93	10,000	219,300	46,817	Mar 31 07:18 PM
Huang Michael F.	Sr. VP of Clinical Development	Mar 27 '25	Sale	69.51	14,583	1,013,627	36,817	Mar 31 07:18 PM
Hirano Patricia C	SEE REMARKS	Mar 27 '25	Option Exercise	7.19	72,140	518,557	166,913	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 28 '25	Option Exercise	33.60	2,691	90,418	58,480	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 27 '25	Sale	68.32	128,653	8,789,717	55,789	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 28 '25	Sale	69.40	27,662	1,919,636	30,818	Mar 31 07:01 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Mar 27 '25	Option Exercise	12.17	523,809	6,373,861	1,100,885	Mar 31 07:00 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Mar 27 '25	Sale	67.62	699,095	47,271,960	577,076	Mar 31 07:00 PM
Vivo Opportunity, LLC	10% Owner	Mar 27 '25	Sale	67.80	1,100,000	74,580,000	4,791,851	Mar 28 07:03 PM
Vivo Opportunity, LLC	10% Owner	Mar 26 '25	Sale	65.80	400,000	26,320,000	5,891,851	Mar 28 07:03 PM
Vivo Opportunity, LLC	10% Owner	Mar 28 '25	Sale	70.60	333,557	23,549,124	4,458,294	Mar 28 07:03 PM
PATRICIA HIRANO	Officer	Mar 28 '25	Proposed Sale	69.40	27,662	1,919,636		Mar 28 04:09 PM
Matthew Pauls	Officer	Mar 28 '25	Proposed Sale	67.39	5,937	400,094		Mar 28 12:45 PM
PATRICIA HIRANO	Officer	Mar 27 '25	Proposed Sale	68.31	111,124	7,591,418		Mar 27 04:15 PM
Kristen Yen	Officer	Mar 27 '25	Proposed Sale	50.05	97,006	4,855,150		Mar 27 08:57 AM
Meredith Manning	Officer	Mar 27 '25	Proposed Sale	50.05	48,000	2,402,400		Mar 27 08:56 AM
James H Mackaness	Officer	Mar 27 '25	Proposed Sale	50.05	92,500	4,629,625		Mar 27 08:55 AM
Michael F. Huang	Officer	Mar 27 '25	Proposed Sale	50.05	29,625	1,482,731		Mar 27 08:55 AM
Patricia C Hirano	Officer	Mar 27 '25	Proposed Sale	50.05	23,375	1,169,919		Mar 27 08:54 AM
Bhatnagar Anish	Officer	Mar 27 '25	Proposed Sale	50.05	746,041	37,339,352		Mar 27 08:53 AM
Yen Kristen	SEE REMARKS	Jan 02 '25	Sale	45.41	2,520	114,431	78,945	Jan 06 09:57 PM
Yen Kristen	SEE REMARKS	Jan 03 '25	Sale	46.18	2,340	108,053	76,605	Jan 06 09:57 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Jan 02 '25	Sale	45.41	4,083	185,406	115,089	Jan 06 09:56 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Jan 03 '25	Sale	46.18	3,791	175,055	111,298	Jan 06 09:56 PM
Hirano Patricia C	SEE REMARKS	Jan 02 '25	Sale	45.41	1,571	71,338	107,361	Jan 06 09:56 PM
Hirano Patricia C	SEE REMARKS	Jan 03 '25	Sale	46.18	1,459	67,371	105,902	Jan 06 09:56 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Jan 02 '25	Sale	45.41	10,937	496,640	708,616	Jan 06 09:55 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Jan 03 '25	Sale	46.18	10,154	468,875	698,462	Jan 06 09:55 PM
Abingworth Bioventures VII LP	Rule 144 Affiliate	Oct 21 '24	Proposed Sale	54.16	949,336	51,416,038		Oct 21 04:30 PM
Abingworth Bioventures VII LP	Rule 144 Affiliate	Oct 07 '24	Proposed Sale	49.63	2,522,751	125,204,132		Oct 07 04:30 PM
Yen Kristen	SEE REMARKS	Oct 01 '24	Sale	49.43	3,108	153,627	81,465	Oct 03 06:03 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Oct 01 '24	Sale	49.43	8,077	399,241	119,172	Oct 03 06:02 PM
Hirano Patricia C	SEE REMARKS	Oct 01 '24	Sale	49.43	3,108	153,627	108,932	Oct 03 05:55 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Oct 01 '24	Sale	49.43	21,633	1,069,306	719,553	Oct 03 05:53 PM
Yen Kristen	SEE REMARKS	Aug 29 '24	Sale	47.28	5,435	256,992	84,573	Aug 30 06:36 PM
Yen Kristen	SEE REMARKS	Aug 28 '24	Sale	47.58	5,270	250,753	90,008	Aug 30 06:36 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Aug 29 '24	Sale	47.28	6,870	324,845	127,249	Aug 30 06:35 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Aug 28 '24	Sale	47.58	6,661	316,938	134,119	Aug 30 06:35 PM
Hirano Patricia C	SEE REMARKS	Aug 29 '24	Sale	47.28	5,435	256,992	112,040	Aug 30 06:34 PM
Hirano Patricia C	SEE REMARKS	Aug 28 '24	Sale	47.58	5,270	250,753	117,475	Aug 30 06:34 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Aug 29 '24	Sale	47.28	58,391	2,760,995	741,186	Aug 30 06:33 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Aug 28 '24	Sale	47.58	56,613	2,693,712	799,577	Aug 30 06:33 PM
Vivo Opportunity, LLC	10% Owner	Aug 27 '24	Sale	48.73	500,000	24,365,000	6,816,851	Aug 29 07:36 PM
Vivo Opportunity, LLC	10% Owner	Aug 28 '24	Sale	47.35	425,000	20,123,750	6,391,851	Aug 29 07:36 PM
Vivo Opportunity, LLC	10% Owner	Aug 29 '24	Sale	47.22	100,000	4,722,000	6,291,851	Aug 29 07:36 PM
Yen Kristen	SEE REMARKS	Aug 06 '24	Sale	45.46	5,957	270,780	95,278	Aug 07 06:57 PM
Yen Kristen	SEE REMARKS	Aug 05 '24	Sale	45.77	5,017	229,618	101,235	Aug 07 06:57 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Aug 06 '24	Sale	45.46	8,134	369,736	140,780	Aug 07 06:56 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Aug 05 '24	Sale	45.77	6,849	313,466	148,914	Aug 07 06:56 PM
Hirano Patricia C	SEE REMARKS	Aug 06 '24	Sale	45.46	5,977	271,689	122,745	Aug 07 06:56 PM
Hirano Patricia C	SEE REMARKS	Aug 05 '24	Sale	45.77	5,032	230,305	128,722	Aug 07 06:56 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Aug 06 '24	Sale	45.46	69,131	3,142,398	856,190	Aug 07 06:55 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Aug 05 '24	Sale	45.77	58,213	2,664,298	925,321	Aug 07 06:55 PM
Yen Kristen	SEE REMARKS	Jul 01 '24	Sale	41.54	2,170	90,136	21,252	Jul 03 06:00 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Jul 01 '24	Sale	41.54	7,190	298,654	55,763	Jul 03 05:58 PM
Hirano Patricia C	SEE REMARKS	Jul 01 '24	Sale	41.54	2,170	90,136	48,754	Jul 03 05:58 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Jul 01 '24	Sale	41.54	19,256	799,844	133,534	Jul 03 05:56 PM
Vivo Opportunity, LLC	10% Owner	Apr 29 '24	Sale	47.80	750,000	35,850,000	7,668,093	May 01 01:10 PM
Vivo Opportunity, LLC	10% Owner	Apr 30 '24	Sale	45.13	351,242	15,851,551	7,316,851	May 01 01:10 PM

Open in Screener

SVRA

Savara Inc

Apr 09 • 04:00PM ET

2.74

Dollar change +0.14
Percentage change 5.38	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI IWM VXF IWO IBB SCHA VTWO ESML VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.48	Insider Own	50.91%	Shs Outstand	172.42M	Perf Week	-8.97%
Market Cap	473.01M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	0.21%	Shs Float	84.75M	Perf Month	7.45%
Income	-95.88M	PEG	-	EPS next Q	-0.13	Inst Own	52.72%	Short Float	19.41%	Perf Quarter	-10.16%
Sales	0.00M	P/S	-	EPS this Y	-9.90%	Inst Trans	2.99%	Short Ratio	15.17	Perf Half Y	-26.74%
Book/sh	0.99	P/B	2.76	EPS next Y	22.91%	ROA	-49.11%	Short Interest	16.45M	Perf Year	-41.45%
Cash/sh	1.14	P/C	2.41	EPS next 5Y	41.72%	ROE	-61.50%	52W Range	2.26 - 5.34	Perf YTD	-10.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.35%	ROI	-48.39%	52W High	-48.69%	Beta	0.46
Dividend TTM	-	Quick Ratio	13.73	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	21.51%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	13.73	EPS Y/Y TTM	-44.25%	Oper. Margin	-	RSI (14)	48.91	Volatility	8.46% 8.41%
Employees	59	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.25	Target Price	9.44
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	-50.61%	Payout	-	Rel Volume	1.08	Prev Close	2.60
Sales Surprise	-	EPS Surprise	-13.74%	Sales Q/Q	-	Earnings	Mar 27 BMO	Avg Volume	1.08M	Price	2.74
SMA20	-2.18%	SMA50	0.57%	SMA200	-22.86%	Trades		Volume	1,193,495	Change	5.38%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
08:05AM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
01:21PM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
08:41PM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace) -5.19%
04:05PM	Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Mar-06-24 04:05PM	Savara to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-02-24 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-31-24 08:05AM	Savara to Present at Two Upcoming Healthcare Conferences (Business Wire)
Dec-30-23 03:01PM	Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA) (GuruFocus.com)
Dec-21-23 08:05AM	Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Dec-20-23 08:05AM	Savara Added to the NASDAQ Biotechnology Index (Business Wire)
Dec-15-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Nov-21-23 08:05AM	Savara to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-09-23 04:05PM	Savara Reports Third Quarter Financial Results and Provides Business Update (Business Wire) -7.84%
Nov-08-23 04:05PM	Savara to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-06-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-27-23 07:29PM	3 Penny Stocks to Provide 1,000% Returns Over the Next Decade (InvestorPlace)
Sep-17-23 10:54AM	15 Penny Stocks with Biggest Upside (Insider Monkey)
Sep-12-23 09:12AM	The 3 Best Penny Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-05-23 04:05PM	Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-10-23 04:05PM	Savara Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
Aug-04-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jul-13-23 07:00AM	Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +8.92%
Jun-26-23 04:05PM	Savara Added to Russell 3000® Index (Business Wire) -7.34%
08:05AM	Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-02-23 08:05AM	Savara to Present at the Jefferies Healthcare Conference (Business Wire)
May-28-23 08:26AM	Independent Director of Savara David Ramsay Buys 4.8% More Shares \ (Simply Wall St.)
May-16-23 12:32PM	Why Shares of Savara Jumped on Tuesday (Motley Fool) +9.09%
May-15-23 08:05AM	Savara Reports First Quarter Financial Results and Provides Business Update (Business Wire)
May-05-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +6.84%
Apr-03-23 07:33AM	Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven In The Near Future (Simply Wall St.) -6.15%
Mar-31-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-30-23 04:05PM	Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update (Business Wire)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -7.31%
Mar-16-23 06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research)
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research) -15.94%
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 04:05PM	Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research)
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research) -7.42%
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
Feb-28-23 04:05PM	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-23-23 07:21AM	Daily Vickers Top Insider Picks for 02/23/2023 (Argus Research)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RAMSAY DAVID A	Director	Mar 31 '25	Buy	2.77	150,000	416,250	2,513,642	Apr 01 07:00 AM
Lowrance David L	Chief Financial Officer	Dec 16 '24	Sale	3.33	25,000	83,278	381,005	Dec 16 05:59 PM
Pauls Matthew	CHIEF EXECUTIVE OFFICER	Dec 16 '24	Sale	3.31	54,702	180,828	1,536,379	Dec 16 05:56 PM
Hawkins Richard J	Director	Dec 16 '24	Sale	3.32	8,000	26,569	67,241	Dec 16 05:53 PM
Pauls Matthew	Director	Dec 16 '24	Proposed Sale	3.31	54,702	180,800		Dec 16 05:13 PM
Hawkins Richard J	Director	Dec 16 '24	Proposed Sale	3.29	8,000	26,300		Dec 16 03:15 PM
Lowrance David L	Officer	Dec 16 '24	Proposed Sale	3.30	25,000	82,500		Dec 16 03:08 PM
McCracken Joseph S	Director	Nov 19 '24	Buy	2.95	20,000	59,072	210,837	Nov 20 07:55 AM
RAMSAY DAVID A	Director	Nov 18 '24	Buy	2.88	100,000	287,600	2,323,642	Nov 18 12:33 PM

SLNO

Soleno Therapeutics Inc

SVRA

Savara Inc

Upgrade your FINVIZ experience